Alan Korman, PhD
Board Member (Vir Pharma)
Alan Korman, PhD, brings more than three decades of immunotherapy and biotechnology experience to his role with BlueSphere Bio. During his 20-year tenure at Medarex and Bristol-Myers Squibb, Dr Korman led the discovery of a revolutionary approach to cancer immune therapy, immune checkpoint blockade. Two of these therapies, Yervoy and Opdivo, alone and in combination, have had an enormous impact on the lives of cancer patients and the direction of cancer therapy research. Dr Korman’s collaboration with Jim Allison, PhD, contributed to Dr Allison’s Nobel Prize-winning research for the discovery of checkpoint inhibition.
Dr Korman received his PhD in Cellular and Developmental Biology from Harvard University, and he has more than 30 patents to his name.